{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:02:03Z","timestamp":1791115323079,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bloodreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.blre.2013.10.002","type":"journal-article","created":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T01:45:41Z","timestamp":1382147141000},"page":"297-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Targeting the ubiquitin proteasome system in haematological malignancies"],"prefix":"10.1016","volume":"27","author":[{"given":"Lisa J.","family":"Crawford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2013.10.002_bb0005","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.febslet.2012.04.053","article-title":"Selectivity of the ubiquitin-binding modules","volume":"586","author":"Rahighi","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.blre.2013.10.002_bb0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.sbi.2011.01.003","article-title":"Structural regulation of cullin-RING ubiquitin ligase complexes","volume":"21","author":"Duda","year":"2011","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.blre.2013.10.002_bb0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4\u00c5 resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.blre.2013.10.002_bb0020","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.blre.2013.10.002_bb0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.17.1.739","article-title":"Degradation of cell proteins and the generation of MHC class I-presented peptides","volume":"17","author":"Rock","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2013.10.002_bb0030","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00018-011-0657-y","article-title":"The role of the proteasome in the generation of MHC class I ligands and immune responses","volume":"68","author":"Sijts","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.blre.2013.10.002_bb0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1006\/bbrc.1995.2878","article-title":"Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells","volume":"217","author":"Imajoh-Ohmi","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2013.10.002_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1042\/bj3170385","article-title":"Apoptosis induction resulting from proteasome inhibition","volume":"317","author":"Shinohara","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.blre.2013.10.002_bb0045","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1073\/pnas.94.3.855","article-title":"Activation of the cell death program by inhibition of proteasome function","volume":"94","author":"Drexler","year":"1997","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2013.10.002_bb0050","first-page":"4342","article-title":"Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor","volume":"58","author":"Orlowski","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0055","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2013.10.002_bb0060","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2006-04-016360","article-title":"Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma","volume":"109","author":"Jakob","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0065","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-08-3034","article-title":"Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome","volume":"15","author":"Ma","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.exphem.2008.11.004","article-title":"Proteasome proteolytic profile is linked to Bcr-Abl expression","volume":"37","author":"Crawford","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0075","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","article-title":"Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132","volume":"66","author":"Crawford","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.blre.2013.10.002_bb0085","series-title":"Multiple Myeloma - An Overview","first-page":"3","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","author":"Crawford","year":"2012"},{"key":"10.1016\/j.blre.2013.10.002_bb0090","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ajh.21374","article-title":"Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo","volume":"84","author":"Edwards","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0100","first-page":"1243","article-title":"Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts","volume":"1","author":"Nawrocki","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2013.10.002_bb0105","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0115","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0120","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.10.002_bb0125","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.10.002_bb0130","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.10.002_bb0135","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2013.10.002_bb0140","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0145","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.10.002_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib combination therapy in multiple myeloma","volume":"49","author":"Kapoor","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0155","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.10.002_bb0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2040620711432020","article-title":"Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma","volume":"3","author":"Mateos","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0165","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","article-title":"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma","volume":"51","author":"Moreau","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.blre.2013.10.002_bb0170","first-page":"309","article-title":"The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed\/refractory multiple myeloma","volume":"34","author":"Lu","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.blre.2013.10.002_bb0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0180","first-page":"w13562","article-title":"Effective response with bortezomib retreatment in relapsed multiple myeloma\u2014a multicentre retrospective survey in Switzerland","volume":"142","author":"Taverna","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.blre.2013.10.002_bb0185","first-page":"755","article-title":"Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series","volume":"6","author":"Wolf","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.blre.2013.10.002_bb0190","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0195","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.2012.45.2177","article-title":"Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75years: CALGB (Alliance) study 10502","volume":"31","author":"Attar","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.10.002_bb0200","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2013.05.011","article-title":"Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"37","author":"Attar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0205","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","article-title":"Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia","volume":"119","author":"Blum","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0215","article-title":"Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia","author":"Walker","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.10.002_bb0220","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","article-title":"Effects of bortezomib on the immune system: a focus on immune regulation","volume":"19","author":"Mohty","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2013.10.002_bb0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbamcr.2004.09.025","article-title":"Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach","volume":"1695","author":"Groll","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.blre.2013.10.002_bb0230","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0235","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0240","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0245","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2011.01602.x","article-title":"Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients","volume":"86","author":"Zangari","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0250","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","article-title":"An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma","volume":"12","author":"Jagannath","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2013.10.002_bb0260","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0265","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0270","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.10.002_bb0275","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0280","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0285","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0290","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","article-title":"Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies","volume":"17","author":"Lee","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0295","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm048995+","article-title":"Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor","volume":"48","author":"Macherla","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2013.10.002_bb0300","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2013.10.002_bb0305","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2010.08144.x","article-title":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model","volume":"149","author":"Singh","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0310","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0315","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","article-title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","volume":"115","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0320","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0325","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/jm7010589","article-title":"Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer","volume":"51","author":"Dorsey","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2013.10.002_bb0330","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","article-title":"The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan","volume":"148","author":"Sanchez","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0335","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","article-title":"A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma","volume":"49","author":"Gallerani","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2013.10.002_bb0340","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2013.10.002_bb0345","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2009-09-243402","article-title":"Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia","volume":"115","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0350","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0355","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.23224","article-title":"Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits","volume":"112","author":"Busse","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.10.002_bb0360","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.10.002_bb0365","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2010.08491.x","article-title":"PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo","volume":"152","author":"Singh","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.10.002_bb0370","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0375","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2009-07-231191","article-title":"The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma","volume":"115","author":"Xu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0380","doi-asserted-by":"crossref","first-page":"23010","DOI":"10.1074\/jbc.C700111200","article-title":"UBE1L2, a novel E1 enzyme specific for ubiquitin","volume":"282","author":"Pelzer","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2013.10.002_bb0385","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0390","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/1087057111433843","article-title":"Identification and mechanistic studies of a novel ubiquitin E1 inhibitor","volume":"17","author":"Ungermannova","year":"2012","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.blre.2013.10.002_bb0400","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pbc.23357","article-title":"Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program","volume":"59","author":"Smith","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2013.10.002_bb0405","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0410","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0415","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-11-0563","article-title":"Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma","volume":"11","author":"McMillin","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2013.10.002_bb0420","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1074\/jbc.M109.089003","article-title":"The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines","volume":"285","author":"David","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2013.10.002_bb0425","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1038\/sj.onc.1207458","article-title":"Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of bortezomib\/proteasome inhibitor PS-341","volume":"23","author":"Chauhan","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2013.10.002_bb0430","first-page":"427","article-title":"Expression and localization of the CDC34 ubiquitin-conjugating enzyme in pediatric acute lymphoblastic leukemia","volume":"12","author":"Eliseeva","year":"2001","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.blre.2013.10.002_bb0435","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2011.05.039","article-title":"An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme","volume":"145","author":"Ceccarelli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.blre.2013.10.002_bb0440","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2012-02-406074","article-title":"Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A","volume":"120","author":"Pulvino","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0445","doi-asserted-by":"crossref","first-page":"e12464","DOI":"10.1371\/journal.pone.0012464","article-title":"In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML","volume":"5","author":"Abdul-Nabi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2013.10.002_bb0450","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1179\/102453309X12473408860389","article-title":"Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia","volume":"14","author":"Hendy","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2013.10.002_bb0455","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-12-473702","article-title":"MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy","author":"Xu-Monette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0460","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/modpathol.2009.170","article-title":"HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis","volume":"23","author":"Liang","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2013.10.002_bb0465","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.V90.5.1982","article-title":"MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells","volume":"90","author":"Teoh","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0470","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-6-23","article-title":"Targeting p53 by small molecules in haematological malignancies","volume":"6","author":"Saha","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2013.10.002_bb0475","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/leu.2011.28","article-title":"Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)","volume":"25","author":"Drakos","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.10.002_bb0480","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/jid.2012.10","article-title":"MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53","volume":"132","author":"Manfe","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.blre.2013.10.002_bb0485","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4161\/cbt.10.6.12535","article-title":"Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways","volume":"10","author":"Saha","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.blre.2013.10.002_bb0490","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/pbc.24235","article-title":"Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program","volume":"60","author":"Carol","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2013.10.002_bb0495","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1535-7163.MCT-10-0337","article-title":"The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias","volume":"9","author":"Kojima","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2013.10.002_bb0500","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-08-0150","article-title":"Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage\u2014independent p53 phosphorylation in mantle cell lymphoma","volume":"14","author":"Jones","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0505","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1182\/blood-2011-03-340323","article-title":"HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma","volume":"118","author":"Jones","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0510","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1756-8722-5-57","article-title":"HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas","volume":"5","author":"Sosin","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2013.10.002_bb0515","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/leu.2008.329","article-title":"Inhibitor of apoptosis proteins in haematological malignancies","volume":"23","author":"Fulda","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.10.002_bb0520","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.leu.2403281","article-title":"Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma","volume":"18","author":"Ansell","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.10.002_bb0525","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.23167","article-title":"Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program","volume":"58","author":"Houghton","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2013.10.002_bb0530","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.leukres.2011.12.024","article-title":"The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac","volume":"36","author":"Ramachandiran","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0535","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/leu.2011.154","article-title":"Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups","volume":"25","author":"Luck","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.10.002_bb0540","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","article-title":"Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia","volume":"27","author":"Schimmer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.10.002_bb0545","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-04-0136","article-title":"Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis","volume":"10","author":"Min","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0550","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-04-1357","article-title":"BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells","volume":"65","author":"Andreu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0555","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0560","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2007-09-112904","article-title":"Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0565","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2013.06.048","article-title":"Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression","volume":"154","author":"Chan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.blre.2013.10.002_bb0570","doi-asserted-by":"crossref","DOI":"10.1210\/en.2013-1757","article-title":"Inhibitors of SCF-Skp2\/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer","author":"Pavlides","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.blre.2013.10.002_bb0575","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/1087057113485789","article-title":"High-throughput screening AlphaScreen Assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1","volume":"18","author":"Ungermannova","year":"2013","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.blre.2013.10.002_bb0580","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.chembiol.2012.09.015","article-title":"Specific small molecule inhibitors of Skp2-mediated p27 degradation","volume":"19","author":"Wu","year":"2012","journal-title":"Chem Biol"},{"key":"10.1016\/j.blre.2013.10.002_bb0585","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.20080277","article-title":"Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7","volume":"205","author":"Thompson","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2013.10.002_bb0590","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1158\/0008-5472.CAN-07-1320","article-title":"FBXW7\/hCDC4 is a general tumor suppressor in human cancer","volume":"67","author":"Akhoondi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.10.002_bb0595","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1084\/jem.20070872","article-title":"The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia","volume":"204","author":"Thompson","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2013.10.002_bb0600","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"O'Neil","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2013.10.002_bb0605","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","article-title":"The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability","volume":"153","author":"King","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.blre.2013.10.002_bb0610","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","article-title":"Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression","volume":"23","author":"Reavie","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2013.10.002_bb0615","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08646","article-title":"Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival","volume":"463","author":"Schwickart","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.blre.2013.10.002_bb0620","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2010-03-276477","article-title":"Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis","volume":"117","author":"Sun","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0625","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/BST0380137","article-title":"The therapeutic potential of deubiquitinating enzyme inhibitors","volume":"38","author":"Colland","year":"2010","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.blre.2013.10.002_bb0630","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2013.10.002_bb0635","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0640","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.V118.21.1433.1433","article-title":"Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 Phase-1 studies","volume":"118","author":"Gupta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0645","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V118.21.302.302","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM)","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.10.002_bb0650","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood.V120.21.203.203","article-title":"A Phase 1b dose-escalation study of split-dose oprozomib (ONX0912) in patients with hematologic malignancies","volume":"120","author":"Savona","year":"2012","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X13000593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X13000593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T05:40:25Z","timestamp":1596692425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X13000593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0268960X13000593"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2013.10.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the ubiquitin proteasome system in haematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2013.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}